Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

ASCO: Trial compares common adjuvant treatments for pancreatic cancer

2009 ASCO Annual Meeting

29 May - 2 Jun 2009

Published: 18 Jun 2009

Views: 13232

Rating:

Save

Dr. John Neoptolemos - University of Liverpool, Liverpool, UK

ASCO press conference: A phase III trial comparing the adjuvant treatments most commonly used for pancreatic cancer in the United States and Europe (gemcitabine and 5- FU/FA, respectively) found that there is no difference in survival between the two regimens, though gemcitabine was associated with fewer side effects.

Categories:
Colorectal & gastro

Related Videos

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine...

Dr Lorraine Chantrill - University of Sydney, Sydney, Australia

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results ( Dr Lorraine Chantrill - University of Sydney, Sydney, Australia )

Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS...

Prof Hironaga Satake - Kochi Medical School, Kochi, Japan

Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC ( Prof Hironaga Satake - Kochi Medical School, Kochi, Japan )

Combination of cabozantinib and atezolizumab shows moderate activity in...

Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain

Combination of cabozantinib and atezolizumab shows moderate activity in treating metastatic adrenocortical carcinoma ( Dr Enrique Grande - MD Anderson Cancer Center Madrid, Madrid, Spain )

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR...

Dr Thierry André - Sorbonne Université, Paris, France

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC ( Dr Thierry André - Sorbonne Université, Paris, France )

Gastro-intestinal endoscopy capacity in Nigeria: strengths and challenges

Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria

Gastro-intestinal endoscopy capacity in Nigeria: strengths and challenges ( Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria )

Colorectal cancer risk factors in Nigeria

Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria

Colorectal cancer risk factors in Nigeria ( Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria )

ESMO 2023: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2023: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Dr Tanvi Sood - Paras hospital, Gurugram, India

GI cancers ( Dr Tanvi Sood - Paras hospital, Gurugram, India )

Active surveillance for oesophageal cancer shows improved HRQoL compared to...

Dr Berend Van der Wilk - Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Active surveillance for oesophageal cancer shows improved HRQoL compared to standard surgery ( Dr Berend Van der Wilk - Erasmus MC Cancer Institute, Rotterdam, The Netherlands )

More from ecancer